INVO Bioscience Completes Merger With NAYA Biosciences Acquisition

MT Newswires Live10-14

INVO Bioscience (INVO) said Monday it has completed its merger with NAYA Biosciences by acquiring all of the outstanding equity interests in the company.

INVO said it issued a combination of shares of its common stock and series C-1 and C-2 preferred stock to NAYA's security holders in connection with the merger.

The combined company expects to change its name to NAYA Biosciences, trade on the Nasdaq under the "NAYA" ticker symbol, continue to operate the fertility business and expand its focus to the development of clinical-stage assets in oncology and autoimmune diseases, INVO said.

INVO said Chief Executive Steve Shum and Chief Financial Officer Andrea Goren, and NAYA's founder and former CEO Daniel Teper, will lead the combined company.

Teper will be named president of the combined company and CEO of the NAYA Therapeutics unit, INVO said.

INVO shares were up 4% in recent Monday trading.

Price: 0.67, Change: +0.03, Percent Change: +4.04

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2475730395?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-14 22:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2475730395","market":"fut","top_or_hot":-1,"title":"INVO Bioscience Completes Merger With NAYA Biosciences Acquisition","media":"MT Newswires Live","content":"<html><body><p> INVO Bioscience (INVO) said Monday it has completed its merger with NAYA Biosciences by acquiring all of the outstanding equity interests in the company.</p><p>INVO said it issued a combination of shares of its common stock and series C-1 and C-2 preferred stock to NAYA's security holders in connection with the merger.</p><p>The combined company expects to change its name to NAYA Biosciences, trade on the Nasdaq under the \"NAYA\" ticker symbol, continue to operate the fertility business and expand its focus to the development of clinical-stage assets in oncology and autoimmune diseases, INVO said.</p><p>INVO said Chief Executive Steve Shum and Chief Financial Officer Andrea Goren, and NAYA's founder and former CEO Daniel Teper, will lead the combined company.</p><p>Teper will be named president of the combined company and CEO of the NAYA <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> unit, INVO said.</p><p>INVO shares were up 4% in recent Monday trading.</p><p>Price: 0.67, Change: +0.03, Percent Change: +4.04</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>INVO Bioscience Completes Merger With NAYA Biosciences Acquisition</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nINVO Bioscience Completes Merger With NAYA Biosciences Acquisition\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-14 22:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>INVO Bioscience (INVO) said Monday it has completed its merger with NAYA Biosciences by acquiring all of the outstanding equity interests in the company.INVO said it issued a combination of shares of ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2475730395","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2475730395","pubTimestamp":1728917967,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"INVO Bioscience  said Monday it has completed its merger with NAYA Biosciences by acquiring all of the outstanding equity interests in the company.INVO said it issued a combination of shares of its common stock and series C-1 and C-2 preferred stock to NAYA's security holders in connection with the merger.The combined company expects to change its name to NAYA Biosciences, trade on the Nasdaq under the \"NAYA\" ticker symbol, continue to operate the fertility business and expand its focus to the development of clinical-stage assets in oncology and autoimmune diseases, INVO said.INVO said Chief Executive Steve Shum and Chief Financial Officer Andrea Goren, and NAYA's founder and former CEO Daniel Teper, will lead the combined company.Teper will be named president of the combined company and CEO of the NAYA Therapeutics unit, INVO said.INVO shares were up 4% in recent Monday trading.Price: 0.67, Change: +0.03, Percent Change: +4.04","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备"},"translate_title":"INVO Bioscience完成与NAYA Biosciences的合并收购","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INVO":1},"content_text":"INVO Bioscience (INVO) said Monday it has completed its merger with NAYA Biosciences by acquiring all of the outstanding equity interests in the company.INVO said it issued a combination of shares of its common stock and series C-1 and C-2 preferred stock to NAYA's security holders in connection with the merger.The combined company expects to change its name to NAYA Biosciences, trade on the Nasdaq under the \"NAYA\" ticker symbol, continue to operate the fertility business and expand its focus to the development of clinical-stage assets in oncology and autoimmune diseases, INVO said.INVO said Chief Executive Steve Shum and Chief Financial Officer Andrea Goren, and NAYA's founder and former CEO Daniel Teper, will lead the combined company.Teper will be named president of the combined company and CEO of the NAYA Therapeutics unit, INVO said.INVO shares were up 4% in recent Monday trading.Price: 0.67, Change: +0.03, Percent Change: +4.04","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2475730395"}